ss1p

SS1P is a recombinant immunotoxin designed for targeted cancer therapy. It consists of an anti-mesothelin variable fragment (Fv), known as SS1, genetically fused to a truncated portion of Pseudomonas exotoxin A (PE38). SS1P binds specifically to mesothelin, a cell surface glycoprotein highly expressed in several human cancers including mesothelioma, ovarian cancer, and pancreatic cancer. Upon binding to mesothelin-expressing tumor cells, SS1P is internalized via receptor-mediated endocytosis and inhibits protein synthesis by delivering the toxin moiety into the cell. This results in cytotoxicity and tumor cell death. Clinical studies have shown that SS1P can induce minor responses or stable disease in patients with advanced mesothelioma and ovarian cancer. The drug has also demonstrated synergy with chemotherapy agents such as pemetrexed/cisplatin and Taxol in preclinical models[2][4][5]. Immunogenicity is common after treatment due to its bacterial toxin component[4]. Delayed anti-tumor immune responses have been observed, suggesting that SS1P may promote immunogenic cell death and sensitize tumors to immune checkpoint blockade therapies such as anti-CTLA-4[6].

Other names

Mesothelin MabMesothelium Antigen Therapy